Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBIT: 2010-2025

Historic EBIT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $98.3 million.

  • Arrowhead Pharmaceuticals' EBIT rose 127.19% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year increase of 116.36%. This contributed to the annual value of $98.3 million for FY2025, which is 116.36% up from last year.
  • Arrowhead Pharmaceuticals' EBIT amounted to $98.3 million in FY2025, which was up 116.36% from -$601.1 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBIT peaked at $98.3 million during FY2025, and registered a low of -$601.1 million during FY2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EBIT value was -$205.0 million (recorded in 2023), while the average stood at -$235.9 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' EBIT slumped by 193.21% in 2024 and then soared by 116.36% in 2025.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' EBIT stood at -$149.0 million in 2021, then fell by 19.77% to -$178.5 million in 2022, then declined by 14.84% to -$205.0 million in 2023, then tumbled by 193.21% to -$601.1 million in 2024, then skyrocketed by 116.36% to $98.3 million in 2025.